Pharmacokinetics and pharmacodynamics of LCZ696, a novel  dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)

Author(s): Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M,  et al.


Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused dose-dependent increases in atrial natriuretic peptide immunoreactivity (due to NEP inhibition) in Sprague-Dawley rats and provided sustained, dose-dependent blood pressure reductions in hypertensive double-transgenic rats. In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours). LCZ696 treatment was associated with increases in plasma cGMP, renin concentration and activity, and angiotensin II, providing evidence for NEP inhibition and angiotensin receptor blockade. In a randomized, open-label crossover study in healthy participants (n = 56), oral LCZ696 400 mg and valsartan 320 mg were shown to provide similar exposure to valsartan (geometric mean ratio [90% confidence interval]: AUC(0-infinity) 0.90 [0.82-0.99]). LCZ696 was safe and well tolerated. These data support further clinical development of LCZ696, a novel, orally bioavailable, dual-acting angiotensin receptor-NEP inhibitor (ARNi) for hypertension and heart failure.

Similar Articles

SOD1 and amyotrophic lateral sclerosis: mutations and  oligomerization

Author(s): Banci L, Bertini I, Boca M, Girotto S, Martinelli M, et  al.

Oral treatment  for multiple sclerosis

Author(s): Killestein J, Rudick RA, Polman CH

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple  sclerosis (MS)

Author(s): Constantinescu CS, Farooqi N, O'Brien K, Gran B

Variable effects of cyclophosphamide in rodent models of  experimental allergic encephalomyelitis

Author(s): Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L,  et al.

[Study of cellular immunity and the opioid peptide system in patients  with multiple sclerosis]

Author(s): Demina TL, BoÄ­ko AN, Rossel's AN, Balashov KE, Popova NF 

Critical role of preproenkephalin in experimental autoimmune  encephalomyelitis

Author(s): Weir C1, McNeill A, Hook S, Harvie M, La Flamme AC, et al. 

The immunoregulatory abilities of polymorphonuclear neutrophils in  the course of multiple sclerosis

Author(s): Ziaber J, PaÅ›nik J, Baj Z, Pokoca L, Chmielewski H, et  al.

Structural analysis of neprilysin with various specific and potent inhibitors

Author(s): Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE

The biology  of the opioid growth factor receptor (OGFr)

Author(s): Zagon IS, Verderame MF, McLaughlin PJ

Opioid growth factor suppresses expression of experimental autoimmune  encephalomyelitis

Author(s): Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ